Lexeo Therapeutics, Inc. · NASDAQ:LXEO
Lexeo Therapeutics — Corporate Update (September 2026)
14 slides from Lexeo Therapeutics's corporate update, Sep 22, 2026
Slide 1: Business Update September 22, 2026
Business Update September 22, 2026 Exhibit 99.2 1
Slide 2: Forward-looking statements
This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, the anticipated benefits of its current product candidates, the timing for r
Slide 3: Reshaping the path of genetic disease
Reshaping the path of genetic disease Our vision: To set a new standard in the treatment of genetic diseases with high unmet need, charting the path to patient outcomes once thought out of reach Genetic disease expertise with cardiovascular and neurological focus Proven experience in the clinic Plat
Slide 4: Building a best-in-class FA platform
Building a best-in-class FA platform Expanding beyond FA-CM to address full burden of FA through complementary modalities, while maintaining financial and executional discipline The combination of these approaches will advance Lexeo’s objective of building a best-in-class, multimodal therapeutic pla
Slide 5: Friedreich Ataxia is a progressive multisystem disease with significant unmet need
Friedreich Ataxia is a progressive multisystem disease with significant unmet need 5 Cardiac complications are the leading driver of mortality, while neurological decline drives substantial lifelong disability; a leading FA platform must address both. Neurological Burden Progressive ataxia, impaired
Slide 6: Expanding the FA platform while maintaining strategic and financial discipline
Expanding the FA platform while maintaining strategic and financial discipline Mantle Acquisition 1 What Lexeo will acquire: 1 Clinical-stage program 2 Preclinical fast followers 1 Discovery program Small molecules Protein replacement RNA-based Three CNS-Targeted Gene Therapy Research Collaborations
Slide 7: Mantle acquisition will add four differentiated approaches to increasing or replacing frataxin
Mantle acquisition will add four differentiated approaches to increasing or replacing frataxin Plan to prioritize investment on the opportunities with the strongest potential for clinical patient impact, regulatory success and shareholder value creation Program Therapeutic approach Stage Route Role
Slide 8: Program highlights: differentiated oral approaches to increase frataxin
Program highlights: differentiated oral approaches to increase frataxin Differentiated oral profile combining robust frataxin upregulation with CNS exposure LX3030 Third-generation oral small molecule (sub-500Da) designed to increase production of endogenous frataxin in the CNS Builds on prior scien
Slide 9: Program highlights: complementary approaches to restore frataxin
Program highlights: complementary approaches to restore frataxin Direct protein replacement diversifies the platform beyond approaches that rely on endogenous frataxin production LX3050 Preclinical recombinant human frataxin fused to a proprietary anti-TfR1 Fab, designed to directly replace deficien
Slide 10: Three new research collaborations supporting sequential dosing of CNS-targeted gene therapy
Three new research collaborations supporting sequential dosing of CNS-targeted gene therapy Sponsored research agreement evaluating intra-cisternal administration of LX2006 following systemic dosing in large animal models. Sequential dosing Option agreement providing the opportunity to secure a lice
Slide 11: Unlocking the full spectrum of FA
Unlocking the full spectrum of FA LX2006 has the potential to serve as the cardiac foundation of a broader multimodal FA platform addressing both cardiac and neurological disease No cardiomyopathy Neuro-predominant disease Mild CM Diagnosed cardiac involvement Moderate CM Moderate cardiac disease Ad
Slide 12: Unlocking the full spectrum of FA
Unlocking the full spectrum of FA Multiple opportunities to address the full spectrum of FA with LX2006 as the backbone LX2006 Best-in-class treatment for FA-CM FXN Increase LX3010 – LX3030 Increase endogenous Frataxin (oral) Neurological Transgene Delivery WCM , Apertura & Vivet Collaborations Enab
Slide 13: Building the leading FA platform through focus, breadth and disciplined execution
Building the leading FA platform through focus, breadth and disciplined execution These transactions will advance Lexeo's objective of building the best-in-class FA platform, with complementary therapeutic approaches that provide a breadth of opportunity unmatched in the FA landscape SUNRISE-FA 2 re
Slide 14: Thank you
Thank you XEO
Lexeo Therapeutics — Corporate Update (September 2026) on 6ix